Interventional Medicine Applied Science Vol 11 2 pp 112116 2019 O R I G I N A L P A P E R Copeptin levels patients coronary artery ectasia OZKAN YAVCIN1 LUTFU ASKIN1 OZLEM SEÇEN2 SERDAR TURKMEN1 ERDAL AKTURK1 OKAN TANRIVERDI1 MUSTAFA NECATI DAGLI3 1Department Cardiology Adiyaman Education Research Hospital Adiyaman Turkey 2Department Cardiology Elazig Education Research Hospital Elazig Turkey 3Department Cardiology Elazig Medical Park Hospital Elazig Turkey Corresponding author Lutfu Askin MD Department Cardiology Adiyaman Education Research Hospital Adiyaman 2230 Turkey Phone 90 531 5203486 Fax 90 4161015 Email lutfuaskin23gmailcom Received February 25 2019 Revised manuscript received March 30 2019 Accepted April 3 2019 Abstract Background aims The etiology pathophysiology coronary artery ectasia CAE fully elucidated A rapid rise plasma copeptin observed cardiovascular diseases stroke sepsis shock This increase diagnostic prognostic value The aim study investigate copeptin relationship CAE Methods This observational prospective study carried October 2012 March 2013 cardiology catheter laboratory inclusion 44 subjects diagnosis CAE 44 age gendermatched individuals normal coronary arteries Blood samples obtained patients stored 70 C analysis copeptin levels sera measured ELISA Results This study comprised 88 study participants 44 patients meeting ectasia criteria mean age 580 115 years 59 n 26 male 44 control subjects angiographically normal coronary anatomy mean age 492 101 years 30 n 13 male Copeptin levels similar groups p 005 In addition correlation copeptin levels CAE Conclusion In study examined copeptin levels elevated CAE patients Keywords cardiovascular diseases coronary artery ectasia copeptin level stroke sepsis Introduction Coronary artery ectasia CAE deﬁned congenital acquired coronary abnormality involving localized diffuse enlargement epicardial coronary artery greater 15 times diameter adjacent normal coronary artery 1 The reported incidence CAE ranges 03 10 1 35 Destruction muscoelastic elements media layer deposition collagen elastin resultant thinning vessel wall represent fundamental processes pathogenesis ectasia 6 7 Injury media layer leads reduced stress tolerance intraluminal pressure eventually causing progressive dilatation ectasia Simultaneous thinning vessel wall increased wall stress create viscous cycle results diffuse local ectasia progressive dilatation coronary artery 8 It reported atheroscle rosis 50 inﬂammatory connective tissue diseases 2030 play important role CAE etiology 9 Copeptin secreted posterior pituitary gland simultaneously vasopressin levels indica tive circulating vasopressin In contrast arginine vasopressin AVP copeptin exhibits higher plasma serum stability allowing easy measurement blood After release remains stable days copep tin levels increase rapidly conditions cardio vascular disease stroke sepsis shock increase indicative elevated AVP secretion diag nostic prognostic implications 10 The etiopathogenesis CAE remains elusive despite number hypotheses proposed Our objective examine relationship copeptin levels CAE This openaccess article distributed terms Creative Commons AttributionNonCommercial 40 International License permits unrestricted use distribution reproduction medium noncommercial purposes provided original author source credited link CC License provided changes indicated DOI 101556164611201908 112 ISSN 20611617 2019 The Authors Coexistence copeptin coronary ectasia Materials Methods This observational prospective study undertaken October 2012 March 2013 cardiolo gy catheter laboratory inclusion 88 subjects diagnosis CAE normal coronary anatomy CAE deﬁned congenital acquired coronary abnormality involving localized diffuse en largement epicardial coronary artery 15 times diameter adjacent normal coronary artery 4 We included CAE patients age sex matched controls The exclusion criteria follows presence kidney failure impaired renal clearance congestive heart failure malignancy hepatic failure actual poten tial pregnancy coexistence coronary lesions associated 50 obstruction acute myocardial infarction MI stroke severe cardiac valve disease previous coronary artery disease CAD history Coronary angiography procedures performed Philips Allura Xper FD10 device Philips Medical Systems Best The Netherlands patients stan dard 6F Judkins right left catheterization following femoral arterial puncture Iodixanol iohexol radiopaque material Images projections obtained recorded digital memory cineﬁlms left right coronary systems respectively In patients suspected ectasia based visual inspection quantitative measurements performed mea surement software Philips Allura Xper FD10 device In order ascertain actual coronary artery lumen width calibration performed catheter diameter CAE deﬁned localized diffuse enlargement epicardial coronary artery 15 times diameter adjacent normal coronary artery Segments stenosis ectasia angiographic images considered normal coronary arterial segments Body mass index BMI calculated subjects height weight The formula BMI kgm2 subjects weight kilogram m2 subjects height meter squared Left ventricular ejection fraction LVEF assessed modiﬁed Simpsons method For blood tests 12 ml venous blood sample collected left antecubital veins patients overnight fasting Samples assessed day sampling Seimens Advia 1800 autoanalyzer device XE5000 Sysmex Corp Kobe Japan Routine biochemical parameters glucose lipid proﬁle urea creatinine complete blood counts hemoglobin hematocrit platelets leukocytes recorded patient For serum copeptin assays 3 ml venous blood placed ethylenediaminetetraacetic acid tubes After tubes gently shaken placed centrifuge centrifuged 3500 rpm 10 min separation sera The resultant samples maintained 70 C time measurements After collection samples serum copeptin levels measured Human Copeptin ELISA Kits Phoneix Pharmaceuticals USA catalog EK06532 lot 603858 microplate readers BioTek Instruments ELx800 USA 450 mg pgml accordance manufacturers instructions 11 The minimum detection concentration linearity maximum measurement concentration kits 012 01214 100 ngml respectively The reported intraassay coefﬁcient variation CV varia tion day interassay variations CV varia tion days kits 10 15 respectively Statistical analyses Statistical analyses performed SPSS 240 soft ware package SPSS Inc Chicago IL USA The normal distribution numerical variables examined KolmogorovSmirnov test For copeptin levels normally distributed logarithmic transformation applied prior statistical analyses Descriptive statistics expressed mean standard deviation numer ical variables number percentage cate gorical variables Betweengroup differences categorical variables analyzed χ2 test independent sample ttest analysis parametric data analysis Correlations variables assessed Pearsons Spearmans correlation coefﬁcient analyses p values 005 considered signiﬁcant Results This study comprised 88 study participants 44 patients meeting ectasia criteria mean age 580 115 years 59 n 26 male 44 control subjects angiographically normal coronary anatomy mean age 492 101 years 30 n 13 male The demographic clinical biochemical assessment char acteristics patients shown Table I Signiﬁcant patient control groups terms frequencies CAD risk factors smoking diabetes hypertension hyperlipidemia p 005 The demographic characteristics age gender signiﬁcantly higher CAE group p 005 The levels LDL creatinine copeptin Fig 1 hemoglobin plasma glucose similar groups p 005 No signiﬁcant differences terms BMI LVEF systolic diastolic blood pressures p 005 Spearmans Pearsons analyses suggested correlation CAE factors Table II Interventional Medicine Applied Science 113 ISSN 20611617 2019 The Authors Table I Demographic clinical biochemical assessment study subjects Yavcin et al Baseline variables Gender male n Age years Hypertension n Smoking n Diabetes mellitus n BMI kgm2 LVEF Systolic BP mmHg Diastolic BP mmHg Plasma glucose mgdl Hemoglobingdl Cre mgdl LDL mgdl Copeptin pmolL Controls n 44 Patients CAE n 44 13 30 4920 1015 10 227 12 273 264 13 582 36 1152 104 728 98 887 214 135 16 078 017 1190 331 79 11 26 59 5807 1153 20 455 13 295 7 159 272 18 574 28 1170 237 750 95 957 294 144 45 086 021 1187 412 82 06 p value 0032 0025 0007 0402 0001 0574 0688 0288 0156 0188 0358 0013 0369 0222 BMI body mass index BP blood pressure Cre creatinine CAE coronary artery ectasia LDL lowdensity lipoprotein LVEF left ventricular ejection fraction Fig 1 Serum copeptin levels groups Discussion This study demonstrated serum copeptin levels similar CAE patients controls No relation ship obvious CAE copeptin levels The reported incidence CAE patient series ranges 03 53 4 Although CAE generally symptoms bears clinical signiﬁ cance regard predisposition cause myocar dial ischemia The etiopathogenesis pathophysiology CAE remains obscure despite hypotheses forward Despite disorder unknown etiopathogen esis generally regarded variant coronary atherosclerosis On hand signiﬁcant pro portion patients CAE associated non atherosclerotic conditions inﬂammatory diseases connective tissue disorders congenital conditions 12 Previous studies reported NO levels shown major role development ectasia inﬂammation 13 14 Copeptin levels rapidly increase conditions cardiovascular disease stroke sepsis shock increase indicative elevated AVP secretion ISSN 20611617 2019 The Authors 114 Interventional Medicine Applied Science Coexistence copeptin coronary ectasia Table II Factors associated coronary artery ectasia Univariate analysis Correlation coefﬁcient r Age LVEF Copeptin Plasma glucose LDL BMI 0129 0156 0208 0222 0052 0089 p value 0161 0369 0102 0092 0654 0322 BMI body mass index LDL lowdensity lipoprotein LVEF left ventricular ejection fraction diagnostic prognostic implications 10 Recently studies examined role novel marker conditions acute MI chronic obstruc tive lung disease sepsis shock In patients presenting MI copeptin shown strong predictor worse outcome prognostic marker death 15 Of note relevance increased combination biomarkers NTproBNP troponins 16 Several authors focused diagnostic perfor mance copeptin setting nonSTsegment elevation acute coronary syndrome chest pain As endogenous stress increased onset acute coronary syndrome copeptin identify acute coro nary syndrome patients biomarkers negative The use dualmarker strategy order rapidly rule diagnosis acute coronary syndrome patients presenting chest pain studied large trials 17 In study Chai et al 18 signiﬁcantly higher copeptin levels CAD patients controls Again plasma copeptin levels exhibited signif icant increase 1 day PTCA coronary stent place ment Despite reduction plasma copeptin levels 3 5 days intervention remained higher controls In study Reichlin et al 19 combined use plasma copeptin troponin T levels higher sensitivity speciﬁcity compared troponin T ruling diagnosis acute MI Copeptin predicts development CAD cardio vascular mortality diabetic nondiabetic patients Copeptin predicts CAD cardiovascular total mortality 20 21 Patients developed cardiac failure died acute MI higher blood copeptin levels Khan et als 22 study In study objective explore rela tionship copeptin levels CAE To best knowledge previous studies reported relationship CAE copeptin levels The copeptin levels play key role diagnosis acute MI prognostic signiﬁcance patients low ejection fraction 23 24 However LVEF measures normal differ groups study CAE frequency associated increased risk factors hyperlipidemia smoking hypertension 2529 In study hyperlipidemia smoking hypertension incidence similar CAE patients controls Plasma copeptin levels tend elevate stress A probable explanation elevated copeptin levels CAD presence lesions associated hemodynami cally signiﬁcant narrowing Thus absence signiﬁcant elevation copeptin levels patient group related fact patients signiﬁcant narrowing Study limitations Less number patients enrolled study rarity isolated CAE In addition sub group analysis CAE performed Another limitation study lack evaluation inﬂammatory markers previous studies exam ined relationship inﬂammation CAE Conclusions In study relationship copeptin levels CAE Further elucidate pathophysiology CAE warranted order develop effective management strategies condition studies Funding sources The funding sponsors role design study collection analyses interpretation data writing manuscript decision publish results Authors contribution OY LA OS prepared manuscript ST gathered data EA OT searched literature MND OY analyzed data All authors read approved ﬁnal version manuscript Conﬂict The authors declare conﬂict regard ing publication paper References 1 Yetkin E Waltenberger J Novel insights old controversy Is coronary artery ectasia variant coronary atherosclerosis Clin Res Cardiol 96 331339 2007 2 Markis JE Joffe CD Cohn PF Feen DJ Herman MV Gorlin R Clinical signiﬁcance coronary arterial ectasia Am J Cardiol 37 217222 1976 Interventional Medicine Applied Science 115 ISSN 20611617 2019 The Authors Yavcin et al 3 Befeler B Aranda MJ Embi A Mullin FL ElSherif N Lazzara R Coronary artery aneurysms Study etiology clinical course effect left ventricular function prognosis Am J Med 62 597607 1977 4 Hartnell GG Parnell BM Pridie RB Coronary artery ectasia Its prevalence clinical signiﬁcance 4993 patients Br Heart J 54 392395 1985 5 Antoniadis AP Chatzizisis YS Giannoglou GD Pathogenetic mechanisms coronary ectasia Int J Cardiol 130 334335 2008 6 Chrissoheris MP Donohue TJ Young RS Ghantous A Coronary artery aneurysms Cardiol Rev 16 116123 2008 7 JianJun L Zheng L Jie L Is link inﬂammation coronary artery ectasia Med Hypotheses 69 678683 2007 8 Gussenhoven EJ Frietman PA The SH van Suylen RJ van Egmond FC Lancée CT Assessment medial thinning atherosclerosis intravascular ultrasound Am J Cardiol 68 16251632 1991 9 Abid AR Jalala SA Gad MG Gehani AA Clinical angiographic features patients coronary artery ectasia compared stenotic coronary artery disease J Cardiol Curr Res 9 00328 2017 10 Morgenthaler NG Copeptin A biomarker cardiovascular renal function Congest Heart Fail 16 3744 2010 11 Ede H Karaçavuş S Göçmen AY Yaylak B Akkaya S Açıkgöz B Serum copeptin level helpful biomarker evaluation myocardial perfusion scintigraphy results Cardiol J 23 7177 2016 12 Gunes Y Boztosun B Yildiz A Metin Esen A Saglam M Bulut M Clinical proﬁle outcome coronary artery ectasia Heart 92 11591160 2006 13 Johanning JM Franklin DP Han DC Carey DJ Elmore JR Inhibition inducible nitric oxide synthase limits nitric oxide production experimental aneurysm expansion J Vasc Surg 33 579586 2001 14 Fukuda S Hashimoto N Naritomi H Nagata I Nozaki K Kondo S Prevention rat cerebral aneurysm formation inhibition nitric oxide synthase Circulation 101 25322538 2000 15 OMalley RG Bonaca MP Scirica BM Murphy SA Jarolim P Sabatine MS Prognostic performance multiple biomarkers patients nonSTsegment elevation acute coronary syndrome Analysis MERLINTIMI 36 trial Metabolic Efﬁciency With Ranolazine Less Ischemia NonSTElevation Acute Coronary SyndromesThrombolysis In Myocardial Infarction J Am Coll Cardiol 63 16441653 2014 16 Lipinski MJ Baker NC Escárcega RO Torguson R Chen F Aldous SJ Comparison conventional highsensitivity tropo nin patients chest pain A collaborative metaanalysis Am Heart J 16 616 2015 17 Möckel M Searle J Hamm C Slagman A Blankenberg S Huber K Early discharge single cardiac troponin copeptin testing patients suspected acute coronary syndrome ACS A randomized controlled clinical process study Eur Heart J 36 369376 2015 18 Chai SB Hui YM Li XM Xiao Y Tang CS Plasma levels copeptin patients coronary heart disease Heart Vessels 24 7983 2009 19 Reichlin T Hochholzer W Stelzig C Laule K Freidank H Morgenthaler NG Incremental value copeptin rapid rule acute myocardial infarction J Am Coll Card 54 6068 2009 20 Tasevska I Enhörning S Persson M Nilsson PM Melander O Copeptin predicts coronary artery disease cardiovascular total mortality Heart 102 127132 2016 21 Enhörning S Hedblad B Nilsson PM Engström G Melander O Copeptin independent predictor diabetic heart disease death Am Heart J 169 549556 2015 22 Khan SQ Dhillon OS OBrien RJ Struck J Quinn PA Morgenthaler NG Cterminal provazopressin copeptin novel prognostic marker acute myocardial infarction Circulation 115 21032110 2007 23 Möckel M Searle J Copeptinmarker acute myocardial infarc tion Curr Atheroscler Rep 16 421 2014 24 Pozsonyi Z Förhécz Z Gombos T Karádi I Jánoskuti L Prohászka Z Copeptin Cterminal pro argininevasopressin independent longterm prognostic marker heart failure reduced ejection fraction Heart Lung Circ 24 359367 2015 25 Pinar Bermúdez E L opez Palop R Lozano MartínezLuengas I Cortés Sánchez R Carrillo Sáez P Rodríguez C Coronary ectasia Prevalence clinical angiographic characteristics Rev Esp Cardiol 56 473479 2003 26 Kruger D Stierle U Herrmann G Simon R Sheikhzadeh A Exerciseinduced myocardial ischemia isolated coronary artery ectasias aneurysms dilated coronopathy J Am Coll Cardiol 34 14611470 1999 27 Adiloglu AK Can R Nazli C Ocal A Ergene O Tinaz G Ectasia severe atherosclerosis Relationships chlamydia pneumo niae helicobacter pylori inﬂammatory markers Tex Heart Inst J 32 2127 2005 28 Yilmaz H Tayyareci G Sayar N Gurkan U Tangurek B Asilturk R Plasma soluble adhesion molecule levels coronary artery ectasia Cardiology 105 176181 2006 29 Von Haehling S Papassotiriou J Morgenthaler NG Hartmann O Doehner W Stellos K Copeptin prognostic factor major adverse cardiovascular events patients coronary artery dis ease Int J Cardiol 162 2732 2012 ISSN 20611617 2019 The Authors 116 Interventional Medicine Applied Science